Bone Marrow & Stem Cell Transplant | Clinical

September 23, 2022

Chenyu Lin, MD, discusses the significance of a 10-year follow up of a study of patients who underwent allogeneic stem cell transplant with the novel cell therapy omidubicel.

August 28, 2022

No significant survival differences were shown between 2 high-dose regimens for newly diagnosed multiple myeloma. However, certain prognostic factors may improve or decrease survival.

August 17, 2022

Chenyu Lin, MD, discusses the results of a 10-year follow up of patients who underwent allogenic stem cell therapy with the novel cell therapy omidubicel.

August 12, 2022

Several priority areas need to be examined in future research to improve the quality of clinical guidelines to address when and how to monitor pediatric hematopoietic stem cell transplant survivors.

August 02, 2022

Robert J. Soiffer, MD, discusses the use of stem cell transplant in treating hematologic malignancies prior to the availability of chimeric antigen receptor T-cell products.

July 14, 2022

Ronald L. Paquette, MD, discusses how age impacts the use of bone marrow and stem cell transplants in patients with myelodysplastic syndrome.

July 11, 2022

In an interview with Targeted Oncology, Anne Wooford, MD, discussed a study of 27 patients with a variety of hematological conditions, unable to find a human leukocyte match donor.

July 06, 2022

Michael R. Bishop, MD, discussed a patient with graft-versus-host disease who first underwent a myeloablative conditioning regimen and peripheral blood stem-cell matched hematopoietic cell transplant as treatment.

June 03, 2022

Within 60 days, the FDA will make a decision on whether to accept the biologics license application for omidubicel as treatment for patients with blood cancers in need of an allogeneic hematopoietic stem cell transplant.

May 17, 2022

Raajit Rampal, MD, PhD, discusses the challenges and unmet needs of myelofibrosis treatments and highlights promising investigational therapies.